Seer (SEER) AI Stock Analysis

• Market Cap: $117.19M
• Dividend Yield: N/A
• Average Volume (3M): 117.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: 12.13%
• EPS Growth: -8.23%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 52,294,370
• 10 Day Avg. Volume: 108,664
• 30 Day Avg. Volume: 117,295
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.52
• Enterprise Value/Revenue: -3.76
• Enterprise Value/Gross Profit: -7.59
• Enterprise Value/Ebitda: 0.74
• 1Y Price Target: $2.00
• Price Target Upside: -3.85% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: $2.00 ▼(-3.85% Downside)

Seer's overall stock score reflects its strong revenue growth and strategic initiatives, but is weighed down by ongoing profitability challenges and negative cash flows. The technical indicators suggest a bearish trend, and valuation metrics are unattractive due to ongoing losses. Despite positive developments in the earnings call, macroeconomic pressures and net losses remain significant concerns.

Positive Factors

Financial Performance

Product revenue grew 73%, exceeding expectations, despite pressure on budgets and extended sales cycles.

Operational Performance

The number of instruments shipped in the quarter matched the total for the entire previous year, demonstrating strong demand and operational performance.

Strategic Initiatives

Management provided positive commentary on customer demand trends including the momentum that's been built by strategic initiatives (STAC and SIP) and awareness from third party publications.

Negative Factors

Government Funding

Uncertain NIH funding is a risk, with significant sales to direct US government labs and US universities.

Market Conditions

Challenging market conditions across Pharma and A&G continue to temper demand and weigh on the stock's performance.

Revenue Visibility

Revenue guidance remains cautious due to uncertainty around government funding and US tariff policies affecting market visibility.

Seer Business Overview & Revenue Model

Company Description

Seer, Inc. (SEER) is a biotechnology company focused on revolutionizing the field of proteomics. The company specializes in developing cutting-edge tools and technologies that enable the comprehensive and precise analysis of proteins at a scale and depth previously unattainable. Seer's core product, the Proteograph Product Suite, is designed to provide researchers with deep insights into the protein compositions of biological samples, facilitating advancements in diagnostics, therapeutics, and biomarker discovery.

How the Company Makes Money

Seer generates revenue through the sale of its Proteograph Product Suite and related consumables, which are essential for conducting proteomic analyses. The company's revenue model primarily includes the direct sale of these products to research institutions, pharmaceutical companies, and academic labs. Additionally, Seer may engage in strategic partnerships and collaborations with other biotech firms and research organizations to expand its market reach and enhance its technological offerings. Through these collaborations, Seer can also generate revenue through licensing agreements and joint development projects.

Seer Financial Statement Overview

Summary

Seer shows modest revenue growth and a strong equity position, but faces significant challenges with profitability and cash flow management. The company's ability to improve revenue growth and manage expenses will be crucial for future financial health.

Income Statement

Seer shows modest revenue growth in the TTM, with a Gross Profit Margin of 40.3%. However, the company faces significant challenges with profitability, as evidenced by a negative Net Profit Margin of -56.6% and negative EBIT and EBITDA margins. Revenue growth has been inconsistent, indicating potential volatility and challenges in sustaining revenue growth.

Balance Sheet

The company has a strong equity position with a low Debt-to-Equity Ratio of 0.08, indicating low leverage. The Equity Ratio stands at 89.6%, which reflects a solid capital structure. However, the consistent negative net income impacts Return on Equity, limiting the potential returns to shareholders.

Cash Flow

Seer has been facing negative Free Cash Flow, although there is a small improvement in the growth rate. The Operating Cash Flow to Net Income ratio reflects challenges in converting income into cash flow, a concern for ongoing operations. The cash flow metrics indicate a reliance on financing activities to support business operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.15M	13.95M	15.18M	14.69M	6.39M	656.00K
Gross Profit	7.99M	6.83M	7.03M	6.74M	3.19M	656.00K
EBITDA	-81.60M	-93.92M	-97.89M	-93.29M	-68.59M	-31.17M
Net Income	-82.44M	-86.60M	-86.28M	-88.70M	-68.63M	-31.17M
Balance Sheet
Total Assets	322.49M	366.60M	436.27M	487.93M	539.14M	442.32M
Cash, Cash Equivalents and Short-Term Investments	209.83M	236.41M	316.22M	421.24M	400.07M	431.86M
Total Debt	24.83M	25.96M	28.26M	29.87M	23.32M	0.00
Total Liabilities	34.20M	39.03M	39.37M	40.94M	36.22M	10.71M
Stockholders Equity	288.29M	327.57M	396.90M	446.99M	502.92M	431.61M
Cash Flow
Free Cash Flow	-54.54M	-49.69M	-66.37M	-71.05M	-53.27M	-25.36M
Operating Cash Flow	-51.66M	-46.11M	-59.06M	-60.78M	-46.35M	-20.83M
Investing Cash Flow	74.26M	65.86M	37.90M	-122.72M	-170.88M	-34.56M
Financing Cash Flow	-16.62M	-11.49M	452.00K	3.89M	116.63M	371.49M

Seer Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.08
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEER, the sentiment is Negative. The current price of 2.08 is below the 20-day moving average (MA) of 2.11, below the 50-day MA of 2.11, and below the 200-day MA of 2.15, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 46.79 is Neutral, neither overbought nor oversold. The STOCH value of 42.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SEER.

Seer Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADCT	54 Neutral	$356.62M	―	123.38%	―	15.73%	38.73%
FDMT	52 Neutral	$304.97M	―	-38.87%	―	―	―
Sector *	51 Neutral	$7.83B	-0.15	-40.10%	2.29%	21.46%	-2.01%
SEER	49 Neutral	$117.19M	―	-25.25%	―	12.13%	-8.23%
SLN	49 Neutral	$243.73M	―	-99.23%	―	-40.10%	-16.60%
VOR	33 Underperform	$260.97M	―	-125.43%	―	―	-686.13%
KLRS	28 Underperform	$42.85M	―	-50.68%	―	―	73.18%

Seer Corporate Events

Seer Faces Nasdaq Compliance Challenge After Annual Meeting

On July 7, 2025, Seer, Inc. informed Nasdaq that it would no longer comply with Nasdaq Listing Rule 5605(c)(2)(A) following its 2025 Annual Meeting of Stockholders. The company plans to utilize the cure period to address the composition of its Audit Committee to regain compliance. During the Annual Meeting, stockholders elected six directors and ratified Deloitte & Touche LLP as the independent accounting firm for the fiscal year ending December 31, 2025.